BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 3304479)

  • 1. [Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial].
    Jouve M; Palangie T; Dorval T; Garcia-Giralt E; Asselain B; Coutant M; Magdelenat H; Pouillart P
    Bull Cancer; 1987; 74(3):249-60. PubMed ID: 3304479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic breast cancer: controlled trial of chemotherapy with and without hormones].
    Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Magdelenat H; Asselain B; Pouillart P
    Bull Cancer; 1984; 71(5):432-41. PubMed ID: 6395920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5 FU. Value of continuous 5 FU perfusion. Results of controlled trials].
    Jouve M; Palangie T; Belli L; Dorval T; Garcia-Giralt E; Beuzeboc P; Scholl S; Mosseri V; Livartowski A; Vedrenne J
    Bull Cancer; 1989; 76(6):643-52. PubMed ID: 2673438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
    Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New methods in the treatment of breast cancer].
    Semiglazov VF
    Vopr Onkol; 1997; 43(1):22-6. PubMed ID: 9133082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
    J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Disseminated breast carcinoma. Study of activity of immunotherapy with BCG and duration of the phase of intensive chemotherapy. Results of a randomized trial (author's transl)].
    Pouillart P; Palangie T; Jouve M; Garcia-Giralt E; Magdelenat H; Asselain B
    Bull Cancer; 1981; 68(1):6-18. PubMed ID: 7013868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised controlled trial of adjuvant hormono-chemotherapy in Stage II breast cancer.
    Holt S; Bradley S; De Sousa BA; Cooke TG; Leinster SJ; George WD
    Eur J Surg Oncol; 1988 Dec; 14(6):663-7. PubMed ID: 3056751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
    Pierce LJ; Hutchins LF; Green SR; Lew DL; Gralow JR; Livingston RB; Osborne CK; Albain KS
    J Clin Oncol; 2005 Jan; 23(1):24-9. PubMed ID: 15545669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II trial of an ambulatory treatment with 5-fluorouracil administered by continuous perfusion combined with vindesine and cyclophosphamide].
    Palangie T; Bastian G; Demarcq C; Dorval T; Jouve M; Garcia-Giralt E; Vedrenne J; Fasano M; Berthau N; Coutant M
    Bull Cancer; 1986; 73(3):279-87. PubMed ID: 3756364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.